Tainted valsartan has been on the market for 4 years, FDA discovers
China’s Zhejiang Huahai Pharmaceutical set off a global recall after it informed global regulators last month that it had discovered the suspected cancer causing impurity N-nitrosodimethylamine in its valsartan API after changing its manufacturing process.
No comments:
Post a Comment